Skip to main content
Premium Trial:

Request an Annual Quote

NIH to Fund 12 Groups with $150M in Total As Part of Renewed PGx Research Network

NEW YORK, Sept. 28 (GenomeWeb News) - The National Institutes of Health will fund 12 groups with more than $150 million over five years in total under its renewed Pharmacogenetics Research Network, the NIH said today.


Originally, the initiative, led by the National Institute of General Medical Sciences and eight other NIH institutes, was funded from 2000 to 2005.


The following groups will receive funding:


-         The Pharmacogenetics and Pharmacogenomics Knowledge Base, headed by Russ Altman at Standford University School of Medicine, will receive $13.7 million;


-         Pharmacogenetics of Nicotine Addiction and Treatment, headed by Neal Benowitz at UCSF, will receive $10 million;


-         The Consortium on Breast Cancer Pharmacogenomics, headed by David Flockhart at Indiana University School of Medicine, will receive $11.6 million;


-         Pharmacogenetics of Membrane Transporters, headed by Kathleen Giacomini at UCSF, will receive $15 million;


-         Pharmacogenomic Evaluation of Antihypertensive Responses, headed by Julie Johnson at the University of Florida, Gainesville, will receive $11.1 million;


-         Pharmacogenetics and Risk of Cardiovascular Disease, headed by Ronald Krauss at UC Berkeley/Lawrence Berkeley National Laboratory, will receive $14.8 million;


-         Functional Polymorphism Analysis in Drug Pathways, headed by Howard McLeod at Washington University, will receive $10.5 million;


-         Pharmacogenetics of Anticancer Agents, headed by Mark Ratain at the University of Chicago and Mary Relling at St. Jude Children's Hospital, will receive $14.9 million;


-         Pharmacogenomics of Arrhythmia Therapy, headed by Dan Roden at Vanderbilt University, will receive $14 million;


-         The Amish Pharmacogenomics of Antiplatelet Intervention Study, headed by Alan Shuldiner at the University of Maryland School of Medicine, will receive $7.5 million;


-         Pharmacogenetics of Phase II Drug Metabolizing Enzymes, headed by Richard Weinshilboum at the Mayo Clinic College of Medicine, will receive $12.6 million;


-         Pharmacogenetics of Asthma Treatment, headed by Scott Weiss at Brigham and Women's Hospital and Harvard Medical School, will receive $16.8 million.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.